Biohaven Pharmaceutical Holding Co (BHVN) Receives a Buy from SVB Securities

In a report issued on May 1, Marc Goodman from SVB Securities maintained a Buy rating on Biohaven Pharmaceutical Holding Co (BHVNResearch Report). The company’s shares closed last Tuesday at $90.10.

According to, Goodman ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.4% and a 41.5% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, Amylyx Pharmaceuticals Inc, and Intra-Cellular Therapies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Biohaven Pharmaceutical Holding Co with a $157.50 average price target, a 69.0% upside from current levels. In a report issued on May 2, Piper Sandler also maintained a Buy rating on the stock with a $170.00 price target.

See today’s best-performing stocks on TipRanks >>

Biohaven Pharmaceutical Holding Co’s market cap is currently $6.35B and has a P/E ratio of -6.85.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Read More on BHVN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More